GoodFellas Big Board Catalyst and Chart Plays

[dDT]

ITMN - Research/DD summary & charts !

InterMune, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies in pulmonology and fibrotic diseases. In pulmonology, the company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It markets pirfenidone, an orally active drug that inhibits the synthesis of TGF-beta under the Esbriet name in the European Union, as well as in a Phase III clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the Pirespa trade name. The company's research programs focus on the discovery of small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. InterMune, Inc. was founded in 1998 and is headquartered in Brisbane, California.

Company's website: http://www.intermune.com/

Financial Reports: http://phx.corporate-ir.net/phoenix.zhtml?c=100067&p=irol-reportsannual

SEC filings: http://phx.corporate-ir.net/phoenix.zhtml?c=100067&p=irol-sec

Nasdaq.com Stock Research - Analyst Summary

http://www.nasdaq.com/symbol/itmn/analyst-research


Contacts

Jim Goff
Vice President
Corporate Communications & Investor Relations
InterMune, Inc.
3280 Bayshore Boulevard
Brisbane, CA 94005
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]

ITMN Chart